Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial - Scorecard - MDSpire
Advertisement
Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial
Clinical Scorecard: Evaluation of Tislelizumab in Combination with Gemcitabine as Initial Therapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma Unfit for Cisplatin: A Phase 2 Single-Center Study
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Care Setting
Phase 2 single-center clinical trial
Key Highlights
mPFS
mOS
Guideline-Based Recommendations
Diagnosis
Assessment of eligibility for cisplatin therapy based on renal function, performance status, and specific comorbidities.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Combination therapy shows promising efficacy and manageable tolerability metrics.
Clinical Best Practices
Monitor and manage specific TRAEs such as leukopenia and neutropenia during treatment.
